The use of targeted mouse models for preclinical testing of novel cancer therapeutics.
about
Institutional shared resources and translational cancer researchMouse models of pancreatic cancerCurrent status and evolution of preclinical drug development models of epithelial ovarian cancerPreclinical mouse cancer models: a maze of opportunities and challenges.Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer.T-cell receptor gene therapy--ready to go viral?Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomesLongitudinal Assessment of Lung Cancer Progression in Mice Using the Sodium Iodide Symporter Reporter Gene and SPECT/CT ImagingHarmonic motion imaging for abdominal tumor detection and high-intensity focused ultrasound ablation monitoring: an in vivo feasibility study in a transgenic mouse model of pancreatic cancerVascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection.A comparison of the imaging performance of high resolution ultrasound scanners for preclinical imaging.Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53Human tumor xenograft models for preclinical assessment of anticancer drug development.A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics.Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluationPancreatic cancer: molecular pathogenesis and new therapeutic targets.Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.Establishment of an orthotopic pancreatic cancer mouse model: cells suspended and injected in Matrigel.Preclinical multimodality phantom design for quality assurance of tumor size measurementAdvancing cancer drug discovery towards more agile development of targeted combination therapies.Lung cancer cell lines as tools for biomedical discovery and researchCholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in miceEffects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance SpectroscopyGeneration of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient miceMetastatic pancreatic cancer is dependent on oncogenic Kras in miceKras as a key oncogene and therapeutic target in pancreatic cancerPET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide.The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model.Tumor-penetrating iRGD peptide inhibits metastasis.Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouseInactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancerTumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.Deploying mouse models of pancreatic cancer for chemoprevention studiesTumor-Endothelial Cell Three-dimensional Spheroids: New Aspects to Enhance Radiation and Drug TherapeuticsHuman tissue in the evaluation of safety and efficacy of new medicines: a viable alternative to animal models?An emerging toolkit for targeted cancer therapies.Mouse models of human bladder cancer as a tool for drug discovery.Gadoxetate acid-enhanced MRI of hepatocellular carcinoma in a c-myc/TGFα transgenic mouse model including signal intensity and fat content: initial experience.Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer
P2860
Q24288943-8AE9093A-DF97-4BD9-A4DB-167F843FB4B0Q26860574-FA5B65DE-7367-4D2E-9113-C650799F84ACQ27028117-BD290143-852B-4BE7-AD48-23EC9FCCA06EQ27322080-052EAAAD-712F-433E-8208-DBB6DECA84EDQ27347648-5FA28AB9-3BC1-4F03-8C89-60B6BE4C9190Q28081611-460C1D7C-CB1C-4B2D-B416-AE49278029BEQ28306591-8A6DFA36-307B-43F8-B4CB-05071EA4311AQ28468469-6BFCFD4A-C790-4A7A-ADD9-392F0B28224CQ30375223-6B71DD68-FF46-42D5-A5CC-5E395245B028Q30416185-2C8A1836-0941-495A-9E37-F2EA0A0ECB93Q30473861-1457C087-305D-4962-84C8-FEFD0F69CBC7Q30498093-1D667060-AF53-4C75-B0D8-F1DC6B91FB5DQ33554319-A7FF69EF-2E53-4142-BE72-4067E7C7DE36Q33792264-1D32A09D-357D-4986-843F-1D5256513D92Q33886981-06274BB6-56AB-4C66-BA86-432A91742D1DQ33899954-0D44DDF1-297F-47EF-8F6E-017D9BBAFBB2Q33934670-63FFFB69-71C7-4950-9F54-B1BD06917B32Q33948383-E08937C6-6C56-4118-8286-E437F1DE8B70Q34035194-39C4BAD8-0106-4BC5-B1EB-6CC0F865BA0AQ34100574-A3084492-85EE-4505-A6AA-F90C97961F15Q34110617-7AB12FAF-7EA0-45AB-A5C4-5546FADC1871Q34167464-ACB78930-B350-4E14-8AC5-65E81593F8B3Q34278997-BED9C93C-80C2-4A28-8AD2-88FE5CBEC3FFQ34372342-C335A3C6-9E9D-449A-9DA4-46FF5A7C0DBFQ34506422-25BB083D-89D3-49D2-A984-CDBC1405E1EAQ34659332-5166996F-1845-4E0C-840C-6E50FEB9F1ACQ34677001-6F0C5E38-DB55-41F3-81C9-7D28384745C5Q34681112-3BCE3F0A-14CD-43FC-8C6C-B7CE6779D494Q34978216-E7565993-9AE1-42F5-A2AA-C16969B77B79Q35022217-557EF09F-CBD2-4991-876C-7F4A68D84865Q35079022-B74EFCEF-B995-4186-93E4-6DB1D0A97ED8Q35534811-3600B8B1-4215-437D-8E81-0AC079506AF8Q35622126-908437B6-EB42-4260-B8EB-85FF6888B63BQ35626527-1C92FEC8-63C8-4668-8CDD-95EB6C160677Q35687753-5C67318F-495A-49A3-8EDA-C660AC75B571Q35694357-809D6F1A-5B01-4A18-BC29-AB7DE86B2091Q35738385-33BDB1F0-8FF7-4ED9-AB3C-06160A0D3D64Q35909487-AC44015E-6A38-4C8C-9791-DD94DD262DE7Q36100853-66308208-0381-4745-9586-7D359516BCA9Q36170279-C4AD7018-BC47-4287-875F-BC97F84D2D87
P2860
The use of targeted mouse models for preclinical testing of novel cancer therapeutics.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The use of targeted mouse models for preclinical testing of novel cancer therapeutics.
@ast
The use of targeted mouse models for preclinical testing of novel cancer therapeutics.
@en
type
label
The use of targeted mouse models for preclinical testing of novel cancer therapeutics.
@ast
The use of targeted mouse models for preclinical testing of novel cancer therapeutics.
@en
prefLabel
The use of targeted mouse models for preclinical testing of novel cancer therapeutics.
@ast
The use of targeted mouse models for preclinical testing of novel cancer therapeutics.
@en
P1476
The use of targeted mouse models for preclinical testing of novel cancer therapeutics
@en
P304
P356
10.1158/1078-0432.CCR-06-0436
P407
P577
2006-09-01T00:00:00Z